All In Biotech

Drug Trial Radar · NCT07808697

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Aug 30, 2029

Study completion Aug 30, 2029

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Sep 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 11 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \<12 years to determine the optimal dose level per age group.

Conditions

  • SARS-CoV-2

Interventions

  • mRNA-1283Biological

    Sterile liquid for injection

  • mRNA-1273Biological

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 and Cohort 2: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Day 1 through Day 7; 7 Days following injection
  2. Cohort 1 and Cohort 2: Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Day 1 through Day 28 (Cohort 1); 28 Days following injection (Cohort 2)
  3. Cohort 1 and Cohort 2: Number of Participants with Any Medically Attended AEs (MAAEs), Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation from the StudyTime frame: Day 1 through End of Study (Month 13)
  4. Cohort 1 and Cohort 2: Geometric Mean Value of Antibody Level Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Target VariantTime frame: Day 29 VISIT (Cohort 1), Day 57 VISIT (Cohort 2)
  5. Cohort 1 and Cohort 2: Geometric Mean Fold Rise of Antibody Level Against SARS-CoV-2Time frame: Day 29 (Cohort 1), Day 57 (Cohort 2)
  6. Cohort 1 and Cohort 2: Number of Participants with Seroresponse RateTime frame: Day 29 (Cohort 1), Day 57 (Cohort 2)

Locations

31 sites in 6 countries. Site status is shown where the registry gives one.

  • Orange County Research Center

    Ontario, California · Recruiting

  • Hope Research Network

    Miami, Florida · Recruiting

  • Spotlight Research Center - Internal Medicine

    Miami, Florida · Recruiting

  • Indago Research and Health Cen

    Miami Lakes, Florida · Recruiting

  • MplusM - D&H Tamarac Research Center

    Tamarac, Florida · Recruiting

  • Eagle Clinical Research, LLC

    Chicago, Illinois · Not yet recruiting

  • Great Lakes Research Institute -Southfield

    Southfield, Michigan · Recruiting

  • Senders Pediatrics

    South Euclid, Ohio · Not yet recruiting

  • REX Clinical Trials

    Beaumont, Texas · Recruiting

  • PanAmerican Clinical Research, LLC.

    Brownsville, Texas · Recruiting

  • South Ogden Family Medicine

    South Ogden, Utah · Recruiting

  • Clinical Research Partners

    Richmond, Virginia · Recruiting

  • Childrens Hospital Regional Medical Center

    Seattle, Washington · Not yet recruiting

  • Fundacion Respirar - Consultorios Medicos Dra De Salvo

    Ciudad Autonoma, Buenos Aires, Argentina · Not yet recruiting

  • Instituto Medico de la Fundacion Estudios Clinicos

    Casilda, Santa Fe Province, Argentina · Not yet recruiting

  • Hospital del Nino Jesus

    San Miguel de Tucumán, Tucumán Province, Argentina · Not yet recruiting

  • Medvacplus Srl Fundacion Clinica Cruz Jiminian

    Cristo Rey, Distrito Nacional (Santo Domingo), Dominican Republic · Not yet recruiting

  • Instituto Dermatologico y Cirugia de Piel ''Dr. Huberto Bogaert Diaz'' (IDCP-DHBD)

    Santo Domingo, Distrito Nacional (Santo Domingo), Dominican Republic · Not yet recruiting

  • Hospital General y de Especialidades Nuestra Señora de la Altagracia

    Salvaleón de Higüey, La Altagracia Province, Dominican Republic · Not yet recruiting

  • Hospital Materno Infantil San Lorenzo De Los Mina

    Santo Domingo, Nacional, Dominican Republic · Not yet recruiting

  • Centro de Investigacion Clínica y Medicina Traslacional (CIMeT)

    Guadalajara, Jalisco, Mexico · Not yet recruiting

  • Hospital Infantil de México Federico Gómez - Pediatric Gastroenterology

    Mexico City, Mexico City, Mexico · Not yet recruiting

  • Instituto Nacional de Pediatria

    Mexico City, Mexico City, Mexico · Not yet recruiting

  • PanAmerican Clinical Research - Queretaro

    Querétaro City, Querétaro, Mexico · Not yet recruiting

  • Centro de Salud Tizimin

    Tizimín, Yucatán, Mexico · Not yet recruiting

  • CEVAXIN Avenida Mexico

    Caledonia, Panama · Not yet recruiting

  • CEVAXIN Chorrera

    La Chorrera, Panama · Not yet recruiting

  • CEVAXIN 24 de Diciembre

    Panama City, Panama · Not yet recruiting

  • Instituto de Investigaciones Cienti-ficas Y Servicios de Alta Tecnologia Asociacion de Interes Panama; . Centro de Investigación, Innovación y Gestión del Conocimiento de Ciudad de la Salud, Caja de Seguro social

    Panama City, Panama · Not yet recruiting

  • Ponce Health Sciences University

    Ponce, Puerto Rico · Recruiting

  • BRCR Global

    San Juan, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.